Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment
HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
HONG KONG, Oct. 14, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that the "Group" was selected as one of the first echelon of enterprises in The ...
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG, June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltdtogether with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"), a non-wholly owned subsidiary of Company, has received a drug registration approval from the Natio...
Sihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing
Accelerating the Layout of Diabetes and Complications HONG KONG, Jan. 4, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announc...
Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.
HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...
Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm
HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu...
Sihuan Pharmaceutical (0460.HK): Say "No" to Smuggled Products - Advocate 'Positive Energy' of China's Medical Aesthetics Industry
HONG KONG, Aug. 11, 2021 /PRNewswire/ -- On June 10, 2021, the National Health Commission, leading eight ministries and commissions, issued the"Notice on Distributing the Special Rectification Work Plan for Combating Illegal Medical Aesthetic Services." On August 9, 2021, 'The People's Daily' pu...
Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea
HONG KONG, June 4, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an Am...
Sihuan Pharmaceutical (0460.HK): 'A Friend of Time' 2021 - The Turning-point Year
HONG KONG, March 16, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in China's domestic medical industry and is a leading company for the development of the country's cardio-cerebral vascular prescription drugs. According to IMS data in 2018, Sihuan Pharmaceut...
Sihuan Pharmaceutical (0460.HK): Be a friend of time, 2021 is the year of turning point
HONG KONG, March 10, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in the domestic medical industry. It is a leading company inChina's CCV prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical is well-known on the national hospital prescrip...
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
Sihuan Pharmaceutical (0460.HK): Xuanzhu Biopharm acquires Combio Pharmaceutical, the large-molecule integrated development platform helps drive innovation
HONG KONG, Jan. 27, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce its innovation Xuanzhu Biopharma...
Sihuan Pharmaceutical (0460) Won the Fifth "Listed Enterprises of the Year 2020" Presented by Bloomberg Businessweek/Chinese Edition
HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Bloomberg Businessweek/Chinese Edition announced thatSihuan Pharmaceutical Holdings Group Ltd. (0460.HK) won the fifth "Listed Enterprises of the Year 2020". The event received enthusiastic support with enterprises from a wide range of industries participat...
Sihuan Pharmaceutical (0460.HK) receives approval for its exclusive medical aesthetic product Letybo (botulinum toxin), A blockbuster product in a hundred-billion size market
HONG KONG, Oct. 27, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460) is pleased announce that "Type A Botulinum Toxin for Injection" (Letybo 100U), a product exclusively distributed by Sihuan Pharmaceutical, has officially received the marketing approval from the Natio...
Sihuan Pharmaceutical's Gabapentin Capsules was Granted Drug Production Approval, the Third Company Obtained Approval in China
HONG KONG, Oct. 22, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(the "Company'' or ''Sihuan Pharmaceutical'', together with its subsidiaries, the ''Group''; HKEX stock code: 0460) is pleased to announce that the National Medical Products Administration has granted drug productio...
Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs
HONG KONG, Oct. 20, 2020 /PRNewswire/ -- On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that its participation in the investment of Phase I Fund of Ascendum Capital Life Te...
Sihuan Pharmaceutical (0460.HK): Under innovation transformation, an internationalized new pattern in construction
HONG KONG, Sept. 15, 2020 /PRNewswire/ -- Recently, share price of Sihuan Pharmaceutical (0460.HK) continued to rise, hittingHK$1.09 per share, up 53.52% from its low onMay 25. Judging from the stock price trend, the stock price of Sihuan Pharmaceutical seems to have entered the stage of reboundi...
SDIC leads the investment of Xuanzhu Biopharmaceutical with RMB 800 million, promoting innovation and R&D
HONG KONG, Aug. 24, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu Biopharmaceutical, its innovative drug research and development platform, su...
Sihuan Pharmaceutical Introduced Investors for Capital Increase to Accelerate Solid-liquid Double Chamber Infusion Soft Bag Industry
HONG KONG, Aug. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Beijing Ruiye Drugs Manufacture Co., Ltd. ("Beijing Ruiye"), an associate of the Grou...
Drug Registration Approval Granted for Sihuan Pharmaceutical's Pediatric Compound Amino Acid Injection (18AA-II)
HONG KONG, March 23, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that drug registration approval has been granted by the National Medical Products Administ...
